Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Neocuproine 是一种铜 (I) 螯合剂,可增强电场刺激引起的输精管收缩的嘌呤能成分,常被用作配位试剂和铜离子检测剂。Neocuproine 与铜离子形成稳定的络合物,并可在某些化学反应和分析方法中起到催化作用。Neocuproine 作为铁和钴上的氧化还原活性配体平台,对NSC34细胞氧化损伤的保护作用。
产品描述 | Neocuproine is a copper(I) chelator that enhances the purinergic component of vasoconstriction induced by electric field stimulation, and is often used as a ligand reagent and copper ion detector.Neocuproine forms stable complexes with copper ions and can play a catalytic role in certain chemical reactions and analytical methods.Neocuproine acts as a redox-active on the iron and cobalt ligand platform for protection against oxidative damage in NSC34 cells. |
体外活性 |
Neocuproine (100 lM) generally inhibits the production of inflammatory mediators.[2] Neocuproine treatment reduced IFN-γ, MCP-1, MCP-3, and VEGF-A levels. The production of KC/GRO was downregulated by neocuproine deficiency.[2] Neocuproine, but not ATP7A deficiency, reduced the production of FGF-9, IL-1α, IL-12p70, IL-2, IL-3, IL-4, IL-6, MIP-1β, MIP-2, RANTES, and TNFα.[2] |
体内活性 |
Neocuproine (100 microM) significantly suppressed the amplitude and frequency of the spontaneous contractions in the ovariectomized non-pregnant rat uterus while this agent facilitated the frequency of the spontaneous or oxytocin-induced contractions in the pregnant rat and human uterus without altering the amplitude of these contractions.[3] Neocuproine (200 microM) could enhance the amplitude of the contractions in the pregnant uterus. These effects were blocked by a purinergic receptor antagonist, suramin (100 microM) and did not occur following the administration of neocuproine-copper(I) complex or copper(II) chelator cuprizone. alpha, beta-methylene ATP increased the amplitude and frequency of contractions in the pregnant uterus, but not affected the contractions in the ovariectomized non-pregnant rat uterus, and neocuproine potentiated this facilitation effect.[3] |
别名 | Neocuproin |
分子量 | 208.26 |
分子式 | C14H12N2 |
CAS No. | 484-11-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45.0 mg/mL (216.1 mM), Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.8017 mL | 24.0085 mL | 48.0169 mL | 120.0423 mL |
5 mM | 0.9603 mL | 4.8017 mL | 9.6034 mL | 24.0085 mL | |
10 mM | 0.4802 mL | 2.4008 mL | 4.8017 mL | 12.0042 mL | |
20 mM | 0.2401 mL | 1.2004 mL | 2.4008 mL | 6.0021 mL | |
50 mM | 0.096 mL | 0.4802 mL | 0.9603 mL | 2.4008 mL | |
100 mM | 0.048 mL | 0.2401 mL | 0.4802 mL | 1.2004 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Neocuproine 484-11-7 Neocuproin Inhibitor inhibitor inhibit